<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987207</url>
  </required_header>
  <id_info>
    <org_study_id>2007.490</org_study_id>
    <nct_id>NCT00987207</nct_id>
  </id_info>
  <brief_title>Pharmacological Postconditioning During the Aortic Valvular Surgery</brief_title>
  <acronym>PC Pharma CVA</acronym>
  <official_title>Pharmacological Postconditioning During the Aortic Valvular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: To evaluate the efficacy of the cyclosporin A administration to induce a
      cardioprotection during the valvular surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The peak of the cardiac troponin I blood level measured during the first 72 hours of surgery follow-up.</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve of the cardiac troponin I release, BNP, length of mechanical ventilation, length of stay in ICU, SAPS, necessity of a catecholaminergic support to assure hemodynamic stability, SAE</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Aortic Valvular Surgery</condition>
  <arm_group>
    <arm_group_label>cyclosporine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single bolus of 2.5 mg/kg, administered before aortic cross-declamping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No cyclosporine A is administered before aortic cross-declamping</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine A</intervention_name>
    <description>a single bolus of 2.5 mg/kg, administered before aortic cross-declamping</description>
    <arm_group_label>cyclosporine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No injection</intervention_name>
    <description>No cyclosporine A is administered before aortic cross-declamping.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females, scheduled for an aortic valvular surgery;

          -  18 years of age or older.

        Exclusion Criteria:

          -  Combined valvular and coronary surgery;

          -  Significant coronary artery stenosis (upper than 70%);

          -  Left ventricular dysfunction (ejection fraction &lt; 40%);

          -  Emergency surgery and/or infectious endocarditis;

          -  Known cyclosporin hypersensitivity;

          -  History of known recent immunosuppression (&lt; 6 months): cancer, lymphoma, positive
             serology for HIV, hepatitis;

          -  Renal insufficiency (creatininaemia &gt; 150 µmol/l);

          -  Hepatic insufficiency (prothrombin time &lt; 50%);

          -  Uncontrolled arterial hypertension defined by a systolic arterial pressure &gt; 180 mm
             Hg;

          -  Women of child bearing potential, who are pregnant or not under efficient
             contraception;

          -  Patients treated with nicorandil, sulfonylurea or rosuvastatine;

          -  Patients under judicial control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal CHIARI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>November 8, 2011</last_update_submitted>
  <last_update_submitted_qc>November 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postconditioning</keyword>
  <keyword>cyclosporine A</keyword>
  <keyword>myocardial ischemia</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>aortic valvulopathy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

